Skip to content

Welcome to Discover Pharma! Today is : November 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

licensing agreement

  • Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    Lonza signs first license deal for NeuroPortal blood-brain barrier technology

    Lonza has signed its first license agreement for its NeuroPortal [...]

    November 17, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China

    Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

    July 15, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation

    Vect-Horus and Servier partner on targeted oligonucleotide therapies for rare CNS diseases

    Vect-Horus has entered a research collaboration and exclusive licence option [...]

    July 3, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Hansa completes €115M Idefirix licensing deal with SERB

    SERB has completed its €115 million licensing agreement with Hansa [...]

    July 2, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Elixirgen signs worldwide option deal with Nippon Shinyaku for Duchenne therapy

    Elixirgen Therapeutics has signed an option agreement with Nippon Shinyaku [...]

    June 29, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Lonza licenses dual-payload ADC technology to Antharis for GI cancers

    Lonza has entered an exclusive licensing agreement with Antharis Therapeutics [...]

    June 16, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Shionogi and BioVersys agree €498M licensing deal for NTM drug candidates

    Deal gives Shionogi access to BioVersys’ BV500 program targeting serious [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • PsiThera raises $25m to advance oral TNFα and TL1A drugs
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • TaiMed reports 80% HIV viral suppression with dual-antibody regimen in Phase 2a study
    Categories: Clinical & Regulatory, Research & Development
  • PlaqueTec expands coronary artery disease trial to eight NHS centres
    Categories: Medical devices, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top